Medicenna Therapeutics to Host Webcast on MDNA11 Clinical Findings
Medicenna Therapeutics Corp. (TSX: MDNA, OTCQX: MDNAF), an innovative clinical-stage immunotherapy company, is gearing up to conduct a live webinar where they will delve into the updated clinical data surrounding MDNA11. This engaging session is set for December 10, 2025, at 08:30 AM Eastern Time.
Exploring MDNA11 at the Webcast
During the webinar, Medicenna will share fresh insights from the ABILITY-1 Phase 1/2 Study. This study assesses MDNA11 both as a monotherapy and in conjunction with pembrolizumab, a leading cancer treatment. With the ESMO Immuno-Oncology Congress 2025 as a backdrop for this data sharing, attendees can expect a comprehensive overview presented by Medicenna's management team, alongside key opinion leaders who will provide additional commentary on the findings.
Webinar Details for Participants
The live format webinar is designed to be interactive, allowing participants to engage through a Q&A session after the presentation. Here are the key details:
Event Information:
Date: December 10, 2025
Time: 08:30 – 09:30 AM ET
Format: Live Webinar with Q&A
Registration: Interested individuals can secure their spot by registering for the webinar on Medicenna’s official website. A replay will also be made available for those who are unable to attend live.
Key Figures in the Spotlight
The webinar will highlight presentations from a distinguished panel comprising Medicenna's executive team and scientific advisors, including:
Featured Speakers:
1. Dr. Fahar Merchant, President and CEO, known for his vision in the advancement of therapeutics.
2. Dr. Arash Yavari, Director of Clinical Strategy, whose expertise leads the company’s clinical trials.
3. Dr. André Mansinho, Assistant Professor from the Faculty of Medicine, University of Lisbon, will present pivotal findings from the ongoing studies.
About Medicenna: Pioneers in Immunotherapy
Medicenna stands at the cutting edge of immunotherapy, emphasizing the development of novel, selective Superkines, targeting IL-2, IL-4, and IL-13 to combat various cancers and inflammatory conditions. MDNA11, their long-acting IL-2 Superkine, is designed with high affinity to CD122, allowing it to preferentially activate effector T cells and NK cells, crucial in the battle against tumors.
In pursuit of cutting-edge treatment options, Medicenna is also advancing MDNA113, a first-of-its-kind PD-1 x IL-2 bispecific agent, which is engineered using proprietary technologies. Their innovative solutions extend to bizaxofusp (formerly known as MDNA55), which is focused on treating recurrent glioblastoma multiforme—a particularly aggressive form of brain cancer. With successful clinical trials and designations such as FastTrack and Orphan Drug status from health authorities, Medicenna continues its mission to revolutionize cancer treatment.
Contact Information for Queries
For any media or investor-related inquiries, individuals are encouraged to reach out to Shushu Feng from the Investor Relations team at Medicenna. Direct contact can be made at (416) 964-5442 or via email at ir@medicenna.com.
Frequently Asked Questions
What is the purpose of Medicenna's upcoming webinar?
The webinar aims to present updated clinical data on MDNA11 and discuss its implications in cancer treatment.
How can I register for the webinar?
Participants can register through Medicenna's official website for an opportunity to engage in Q&A.
Who are the key speakers for the event?
Key speakers include Dr. Fahar Merchant, Dr. Arash Yavari, and Dr. André Mansinho, who will be sharing valuable insights.
What topics will be covered in the webinar?
The webinar will cover updates on the ABILITY-1 Phase 1/2 Study, focusing on MDNA11’s effectiveness.
How does MDNA11 work?
MDNA11 is designed to selectively stimulate cancer-fighting cells, enhancing their ability to combat tumors while minimizing side effects.
